On September 30, 2021 Optieum Biotechnologies reported that the company has raised JPY 290 million ($ 2.6 million) in seed round funding (Press release, Optieum Biotechnologies, SEP 30, 2021, View Source [SID1234639140]). The round was led by ANRI and the participation of Real Tech Fund, Iyogin Capital and an angel investor.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Optieum Biotechnologies Inc. is a biotechnology company committed to develop innovative scFv antibody-based therapies for the treatment of cancer patients. Our proprietary platform technology, Eumbody System, enables us to develop and detect scFv-based product candidates that specifically bind, modulate, and ultimately enhance the immune-cell function for oncology targets.

With this funding, we will continue to expand the platform technology and accelerate the collaboration with pharmaceutical companies as well as the development of in-house CAR-T cell programs.

We are committed to go beyond the limits of immuno-oncology drug development and deliver the most appropriate treatment for the cancer patients in needs.